Growth Metrics

Pfizer (PFE) Cash from Discontinued Operations (2020 - 2022)

Pfizer has reported Cash from Discontinued Operations over the past 9 years, most recently at 5000000.0 for Q3 2022.

  • Quarterly Cash from Discontinued Operations fell 129.41% to 5000000.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was 332000000.0 through Oct 2022, down 115.84% year-over-year, with the annual reading at 343000000.0 for FY2021, 108.88% down from the prior year.
  • Cash from Discontinued Operations was 5000000.0 for Q3 2022 at Pfizer, up from 327000000.0 in the prior quarter.
  • Over five years, Cash from Discontinued Operations peaked at 2414000000.0 in Q3 2020 and troughed at 327000000.0 in Q4 2021.
  • The 3-year median for Cash from Discontinued Operations is 17000000.0 (2021), against an average of 564428571.43.
  • Year-over-year, Cash from Discontinued Operations tumbled 98.07% in 2021 and then plummeted 129.41% in 2022.
  • A 3-year view of Cash from Discontinued Operations shows it stood at 2414000000.0 in 2020, then plummeted by 113.55% to 327000000.0 in 2021, then skyrocketed by 98.47% to 5000000.0 in 2022.
  • Per Business Quant, the three most recent readings for PFE's Cash from Discontinued Operations are 5000000.0 (Q3 2022), 327000000.0 (Q4 2021), and 17000000.0 (Q3 2021).